

NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.

4 August 2017

Oncolys BioPharma Inc.

## Announcement of Non-Operating Losses

Oncolys BioPharma (“Oncolys”) announces today that non-operating losses were recorded in the non-consolidated cumulative second quarter (1/1/2017 - 30/6/2017) as follows:

### 1. Details of non-operating losses

Due to recent fluctuations in foreign currency exchange rates, in the non-consolidated cumulative second quarter (1/1/2017 – 30/6/2017), foreign exchange losses of JPY 7,780,000 were recorded as non-operating losses. As a result, together with other items, non-operating losses of JPY 9,377,000 were posted in the same cumulative second quarter (1/1/2017 – 30/6/2017).

The announcement above will not affect Oncolys’ earnings for the fiscal year ending 31 December 2017.

**Ends**

###

### **About Oncolys BioPharma Inc.**

*Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS.*

*For more information, please visit <http://www.oncolys.com/en/>*

<b>Oncolys BioPharma Inc.</b>	
Mie Yamazaki Investor Relations & Corporate Communications Tel: +81 (0) 5472 1578 Email: yamazaki@oncolys.com	